Dyadic Applied BioSolutions and Proliant Health & Biologicals announced the commercial launch of AlbuFree DX, a recombinant human albumin (rHA) produced on Dyadic’s proprietary filamentous fungal C1 platform. The product became available on February 17, 2026, marking the first major commercial milestone for Dyadic’s protein portfolio.
Under the partnership, Dyadic supplies the recombinant protein and technology while Proliant, a global producer of albumin and other purified proteins, delivers the finished product through its established distribution network. Dyadic will receive a share of profits from Proliant’s sales of AlbuFree DX, positioning the company to capture demand for animal‑free, scalable inputs in cell culture media and other life‑science applications.
The launch validates Dyadic’s strategic pivot toward near‑term commercialization of high‑value, non‑pharmaceutical proteins. By partnering with an experienced manufacturer, Dyadic can accelerate market entry, reduce time‑to‑revenue, and demonstrate the commercial viability of its C1 platform. The company has set a target to achieve cash‑flow positivity by the end of 2026, and the new revenue stream is expected to contribute materially to that goal.
Dyadic’s financial performance in the third quarter of 2025 ended with a net loss of $0.06 per share and revenue of $1.165 million, falling short of analyst expectations. The company maintains a healthy current ratio of 2.85 and holds more cash than debt, but it has received a Nasdaq deficiency notice for not meeting the minimum bid price of $1 per share, with a compliance deadline of June 17, 2026. The partnership with Proliant and the AlbuFree DX launch represent a strategic effort to strengthen the company’s financial footing.
The recombinant human albumin market is estimated at approximately $6 billion, and demand for animal‑free protein sources has been rising across cell culture, diagnostics, and bio‑industrial sectors. Proliant plans to expand the AlbuFree product line later in 2026 with a formulation specifically tailored for the cell culture market, further broadening the addressable market for Dyadic’s technology.
Joe Hazelton, President and Chief Operating Officer of Dyadic, said, "This launch is a clear validation of Dyadic's technology and our commercialization strategy." He added, "Recombinant human albumin is a well‑understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner‑driven commercialization model." Hazelton further noted, "This milestone demonstrates that Dyadic's microbial platforms are well‑suited for products that can be efficiently integrated into existing manufacturing, quality, and commercial infrastructures. We believe this further reinforces the applicability of Dyadic's technology for scalable commercialization in large, established markets." Chris Detzel, President and CEO of Proliant Health & Biologicals, stated that AlbuFree DX "builds on that foundation by adding a high‑quality, animal‑free recombinant human albumin to our diagnostic market portfolio." He added, "AlbuFree™ DX builds on that foundation by adding a high‑quality, animal‑free recombinant human albumin to our diagnostic market portfolio, allowing us to meet growing customer demand while maintaining the consistency, reliability, and scale our customers expect."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.